Digital spatial profiling for identification of prognostic genes and molecular subgroups in pleural mesothelioma.

M Mercedes Herrera (Hospital Universitario 12 de Octubre, Madrid, Spain) D David Lora (Faculty of Statistics, Complutense University of Madrid, Madrid, Spain) M Melina Peressini (Instituto de Investigación Hospital 12 de Octubre, Madrid, Spain) R Ramon Yarza (START Madrid, Madrid, Spain) J Jose Maria Gracia (H12O-CNIO Lung Cancer Clinical Research Unit, Health Research Institute Hospital Universitario 12 de Octubre (i+12), Madrid, Spain) Álvaro C. Ucero (H12O-CNIO Lung Cancer Clinical Research Unit, Health Research Institute Hospital Universitario 12 de Octubre (i+12), Madrid, Spain) M Magdalena Molero Abraham (Tumor Microenvironment and Immunotherapy Research Group, Instituto de Investigación Hospital 12 de Octubre (i+12), Madrid, Spain) A Ana Belén Enguita (Department of Pathology. Hospital Universitario 12 de Octubre, Madrid, Spain) D David Gómez-Sánchez (H12O-CNIO Lung Cancer Clinical Research Unit, Health Research Institute Hospital Universitario 12 de Octubre (i+12), Madrid, Spain) V Vera Adradas Rodriguez (Tumor Microenvironment and Immunotherapy Research Group, Instituto de Investigación Hospital 12 de Octubre (i+12), Madrid, Spain) E Esther Conde (Pathology Department, Hospital Universitario 12 de Octubre, Universidad Complutense de Madrid, Research Institute Hospital 12 de Octubre (i+12), CIBERONC, Madrid, Spain) N Nuria Carrizo (Department of Pathology, Hospital Universitario 12 de Octubre, Madrid, Spain) I Igor Gomez-Randulfe R Roxana Reyes N Noemi Reguart (Medical Oncology Department, Hospital Clinic y Provincial de Barcelona, Barcelona, Spain) J Javier Baena H Helena Bote de Cabo (Hospital Universitario 12 de Octubre, Madrid, Spain) S Santiago Ponce Aix (Hospital Universitario 12 de Octubre, Madrid, Spain) L Luis G. Paz-Ares (Department of Medical Oncology, Hospital 12 de Octubre, Madrid, Spain) J Jon Zugazagoitia (Department of Medical Oncology, 12 de Octubre Hospital, Madrid)

Abstract

8084 Background: Pleural mesothelioma (PM) is an aggressive malignancy that harbors significant inter- and intra-tumoral heterogeneity. Spatial transcriptomics enables the dissection of the tumor's molecular architecture by facilitating compartment-specific gene expression profiling. We performed high-resolution RNA-seq analysis of tumor (Tm) and stroma (St) compartments in PM samples to identify gene expression patterns and their association with clinical outcomes. Methods: Formalin-fixed paraffin-embedded (FFPE) tumor samples from untreated PM patients (pts) across three institutions were analyzed using the NanoString GeoMx Digital Spatial Profiling (DSP) platform. Regions of interest (ROIs) were selected based on histopathological features and fluorescently labeled antibodies for tumor and stromal areas. RNA expression of >1800 genes from selected ROIs was analyzed using GeoMx Cancer Transcriptome Atlas (CTA). Differential gene expression was assessed utilizing R “limma” package. A cutoff of absolute fold change ≥1 and p-value <0.05, with the Benjamini-Hochberg false discovery rate method, was applied to identify significant differentially expressed genes (DEGs). Elastic Net regression optimized through cross-validation methods was employed to identify genes associated with overall survival (OS) outcomes. Data from the TCGA PanCancer Atlas was utilized for external validation. Results: A total of 72 pts, 80.3% male, median age of 71y (range: 44-94) were identified for the analysis. Among them, 87.5% (63/72) were epithelioid (Ep) and 12.5% (9/72) non-epithelioid (NEp). After quality control, RNA data was available from 71 and 67 pts in Tm and St compartments, respectively. Across 132 ROIs in the Tm compartment, we identified 4 significantly DEGs between NEp (upregulated COL5A2, THBS1 ; downregulated CLU, KRT19 ) and Ep subgroups. No DEG between Ep and NEp subgroups were identified in 115 ROIs from the St compartment. Unsupervised clustering identified four molecular subgroups with distinct gene expression in the Tm compartment, of which Cluster 1 showed significantly decreased OS (6.3m vs. 16.4m; HR 3.3, p =0.001). Elastic Net regression identified 31 genes predictive of OS (R² = 0.43, Harrell’s c-index = 0.87), including nine genes ( IFNGR2, FCER1G, MFGE8, CKLF, CBL, HLA-DRB3, HK1, PLAT, CD163 ) associated with worse prognosis. Tumors in Cluster 1 demonstrated higher expression of these genes. External validation using the TCGA cohort confirmed four genes IFNGR2 ( p = 0.02), CBL ( p = 0.01), HK1 ( p <0.001), PLAT ( p <0.001), as significantly associated with decreased OS in PM. Conclusions: Spatially resolved transcriptomic profiling suggests Tm-enriched regions as the primary drivers of PM subtype and aggressiveness, identifying nine genes and a molecular subgroup associated with poorer survival outcomes. Further validation and functional studies are warranted.

Article Details

Volume / Issue Vol. 43, Issue 16_suppl
Published June 01, 2025
Pages 8084-8084
ISSN 0732-183X
Publisher Lippincott Williams & Wilkins

Journal Info

Journal of Clinical Oncology

Lippincott Williams & Wilkins

ISSN: 0732-183X Health Sciences

Authors (20)

M

Mercedes Herrera

Hospital Universitario 12 de Octubre, Madrid, Spain

D

David Lora

Faculty of Statistics, Complutense University of Madrid, Madrid, Spain

M

Melina Peressini

Instituto de Investigación Hospital 12 de Octubre, Madrid, Spain

R

Ramon Yarza

START Madrid, Madrid, Spain

J

Jose Maria Gracia

H12O-CNIO Lung Cancer Clinical Research Unit, Health Research Institute Hospital Universitario 12 de Octubre (i+12), Madrid, Spain

Álvaro C. Ucero

H12O-CNIO Lung Cancer Clinical Research Unit, Health Research Institute Hospital Universitario 12 de Octubre (i+12), Madrid, Spain

M

Magdalena Molero Abraham

Tumor Microenvironment and Immunotherapy Research Group, Instituto de Investigación Hospital 12 de Octubre (i+12), Madrid, Spain

A

Ana Belén Enguita

Department of Pathology. Hospital Universitario 12 de Octubre, Madrid, Spain

D

David Gómez-Sánchez

H12O-CNIO Lung Cancer Clinical Research Unit, Health Research Institute Hospital Universitario 12 de Octubre (i+12), Madrid, Spain

V

Vera Adradas Rodriguez

Tumor Microenvironment and Immunotherapy Research Group, Instituto de Investigación Hospital 12 de Octubre (i+12), Madrid, Spain

E

Esther Conde

Pathology Department, Hospital Universitario 12 de Octubre, Universidad Complutense de Madrid, Research Institute Hospital 12 de Octubre (i+12), CIBERONC, Madrid, Spain

N

Nuria Carrizo

Department of Pathology, Hospital Universitario 12 de Octubre, Madrid, Spain

I

Igor Gomez-Randulfe

R

Roxana Reyes

N

Noemi Reguart

Medical Oncology Department, Hospital Clinic y Provincial de Barcelona, Barcelona, Spain

J

Javier Baena

H

Helena Bote de Cabo

Hospital Universitario 12 de Octubre, Madrid, Spain

S

Santiago Ponce Aix

Hospital Universitario 12 de Octubre, Madrid, Spain

L

Luis G. Paz-Ares

Department of Medical Oncology, Hospital 12 de Octubre, Madrid, Spain

J

Jon Zugazagoitia

Department of Medical Oncology, 12 de Octubre Hospital, Madrid